Rock Springs Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Rock Springs Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-75,000	Closed	-$1.59M	–	122
2015 Q2	$1.59M	Sell	75,000 -385,000	-84%	-$6.9M	0.12%	112
2015 Q1	$8.27M	Sell	460,000 -215,000	-32%	-$3.37M	0.77%	44
2014 Q4	$11.6M	Sell	675,000 -60,000	-8%	-$857K	1.35%	21
2014 Q3	$10.5M	Sell	735,000 -40,000	-5%	-$575K	1.63%	16
2014 Q2	$11.6M	Buy	775,000 +25,000	+3%	+$302K	2.08%	14
2014 Q1	$10.1M	Buy	+750,000	New	+$8.04M	2.32%	14

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Rock Springs Capital Management's AVDL Position: Q3 2015 in Review

Rock Springs Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2015, closing a stake of 75,000 shares — an estimated $1.59M sold.

Rock Springs Capital Management first reported a position in AVDL in Q1 2014 and held it in 6 quarters. The position peaked at $11.6M in Q2 2014. 97 funds tracked by Wall St. Rank hold AVDL as of Q3 2015.

Rock Springs Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Rock Springs Capital Management sold 75,000 Avadel Pharmaceuticals shares in Q3 2015, an estimated $1.59M.
Rock Springs Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Rock Springs Capital Management's Avadel Pharmaceuticals position peaked at $11.6M in Q2 2014.
97 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2015.

Based on Rock Springs Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.